Preventing CMV with letermovir after kidney or liver transplant
Treatments studied
Part of Digestive system, Kidney & urinary clinical trials.
This study tests a drug called letermovir to see if it can help prevent a common virus called CMV from causing problems after your transplant. It's for people who have had a kidney or liver transplant and carry the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You had a kidney transplant, liver transplant, or both.
- You tested positive for CMV (a common virus) before your transplant.
- You don't have an allergy to the study drug letermovir.
- You're not already in another CMV-related study.
- You're willing to follow the study plan and attend visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study tests a new drug called letermovir, given after a lung transplant, to see if it prevents CMV infection better than the current standard drug, valganciclovir. If you're at high risk for CMV, this trial could help protect you from this common post-transplant infection.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.